Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2006 2
2007 2
2009 2
2010 2
2011 4
2012 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Results by year
Filters applied: . Clear all
Page 1
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis.
Soverini S, Vitale A, Poerio A, Gnani A, Colarossi S, Iacobucci I, Cimino G, Elia L, Lonetti A, Vignetti M, Paolini S, Meloni G, di Maio V, Papayannidis C, Amabile M, Guarini A, Baccarani M, Martinelli G, FoĆ  R. Soverini S, et al. Among authors: Gnani A. Haematologica. 2011 Apr;96(4):552-7. doi: 10.3324/haematol.2010.034173. Epub 2010 Dec 29. Haematologica. 2011. PMID: 21193419 Free PMC article.
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
Soverini S, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S, Merante S, Orlandi E, de Matteis S, Gozzini A, Iacobucci I, Palandri F, Gugliotta G, Papayannidis C, Poerio A, Amabile M, Cilloni D, Rosti G, Baccarani M, Martinelli G. Soverini S, et al. Among authors: Gnani A. Blood. 2009 Sep 3;114(10):2168-71. doi: 10.1182/blood-2009-01-197186. Epub 2009 Jul 9. Blood. 2009. PMID: 19589924 Clinical Trial.
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M, Martinelli G. Soverini S, et al. Among authors: Gnani A. Haematologica. 2007 Mar;92(3):401-4. doi: 10.3324/haematol.10822. Haematologica. 2007. PMID: 17339191 Free article. Clinical Trial.
Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.
Intermesoli T, Castagnetti F, Soverini S, Bussini A, Spinelli O, Gnani A, Bassan R, Rosti G. Intermesoli T, et al. Among authors: Gnani A. Leuk Res. 2012 Jan;36(1):e10-1. doi: 10.1016/j.leukres.2011.09.002. Epub 2011 Oct 1. Leuk Res. 2012. PMID: 21962337 No abstract available.
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
Soverini S, Martinelli G, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M. Soverini S, et al. Among authors: Gnani A. J Clin Oncol. 2006 Nov 20;24(33):e51-2. doi: 10.1200/JCO.2006.08.9128. J Clin Oncol. 2006. PMID: 17114651 No abstract available.
IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis.
Soverini S, Score J, Iacobucci I, Poerio A, Lonetti A, Gnani A, Colarossi S, Ferrari A, Castagnetti F, Rosti G, Cervantes F, Hochhaus A, Delledonne M, Ferrarini A, Sazzini M, Luiselli D, Baccarani M, Cross NC, Martinelli G. Soverini S, et al. Among authors: Gnani A. Leukemia. 2011 Jan;25(1):178-81. doi: 10.1038/leu.2010.236. Epub 2010 Oct 21. Leukemia. 2011. PMID: 20962862 No abstract available.
Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
Potenza L, Volzone F, Riva G, Soverini S, Martinelli S, Iacobucci I, Gnani A, Barozzi P, Forghieri F, Morselli M, Zanetti E, Maccaferri M, Baccarani M, Martinelli G, Torelli G, Luppi M. Potenza L, et al. Among authors: Gnani A. Br J Haematol. 2009 Jul;146(2):227-30. doi: 10.1111/j.1365-2141.2009.07747.x. Epub 2009 May 26. Br J Haematol. 2009. PMID: 19545285 No abstract available.
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib.
Soverini S, Gnani A, De Benedittis C, Castagnetti F, Gugliotta G, Iacobucci I, Palandri F, Rosti G, Testoni N, Luatti S, Marzocchi G, Baccarani M, Martinelli G. Soverini S, et al. Among authors: Gnani A. Leuk Res. 2011 Nov;35(11):1527-9. doi: 10.1016/j.leukres.2011.05.029. Epub 2011 Jul 16. Leuk Res. 2011. PMID: 21762985
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL.
Soverini S, Martinelli G, Colarossi S, Gnani A, Rondoni M, Castagnetti F, Paolini S, Rosti G, Baccarani M. Soverini S, et al. Among authors: Gnani A. Lancet Oncol. 2007 Mar;8(3):273-4. doi: 10.1016/S1470-2045(07)70078-5. Lancet Oncol. 2007. PMID: 17329198 No abstract available.
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abruzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, di Lorenzo R, Caracciolo C, Izzo B, Pane F, Saglio G, Baccarani M, Martinelli G; GIMEMA Working Party on Chronic Myeloid Leukemia. Soverini S, et al. Among authors: Gnani A. Clin Cancer Res. 2006 Dec 15;12(24):7374-9. doi: 10.1158/1078-0432.CCR-06-1516. Clin Cancer Res. 2006. PMID: 17189410 Free article. Clinical Trial.
11 results
Jump to page
Feedback